Evidence map›Paper›PMID 28646169›Full record

Trial reportScientific reports2017

Improving Dialysis Adherence for High Risk Patients Using Automated Messaging: Proof of Concept.

A Som, J Groenendyk, T An, K Patel, R Peters, G Polites, W R Ross

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. [Digital nephrology].Der nephrologe · 2021
    Article
  11. Disinfectants in a Hemodialysis Setting: Antifungal Activity AgainstFrontiers in cellular and infection microbiology · 2021
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A SomEpharmix Research Center, Washington University School of Medicine, St. Louis, USA.
J GroenendykEpharmix Research Center, Washington University School of Medicine, St. Louis, USA.
T AnEpharmix Research Center, Washington University School of Medicine, St. Louis, USA.
K PatelSaint Louis University School of Medicine, St. Louis, USA.
R PetersEpharmix Research Center, Washington University School of Medicine, St. Louis, USA.ORCID 0000-0003-1828-0525
G PolitesDivision of Emergency Medicine, Washington University School of Medicine, St. Louis, USA.
W R RossEpharmix Research Center, Washington University School of Medicine, St. Louis, USA. rossw@wustl.edu.ORCID 0000-0002-8112-2979

Funding

A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCERF30CA189435 · NCI · WASHINGTON UNIVERSITY · PI SOM, AVIK · 2014 to 2017
$135k
NCI NIH HHS F30 CA189435
6 · The paper itself

Abstract

Comorbidities and socioeconomic barriers often limit patient adherence and self-management with hemodialysis. Missed sessions, often associated with communication barriers, can result in emergency dialysis and avoidable hospitalizations. This proof of concept study explored using a novel digital-messaging platform, EpxDialysis, to improve patient-to-dialysis center communication via widely available text messaging and telephone technology. A randomized controlled trial was conducted through Washington University-affiliated hemodialysis centers involving ESRD patients with poor attendance, defined as missing 2-6 sessions over the preceding 12 weeks. A cross-over study design evaluated appointment adherence between intervention and control groups. Comparing nonadherence rates eight weeks prior to enrollment, median appointment adherence after using the system increased by 75%, and median number of unintended hospitalization days fell by 31%. A conservative cost-benefit analysis of EpxDialysis demonstrates a 1:36 savings ratio from appointment adherence. EpxDialysis is a low-risk, cost-effective, intervention for increasing hemodialysis adherence in high-risk patients, especially at centers caring for vulnerable and low-income patients.

Indexed as

Renal DialysisText MessagingAdultAutomationCost-Benefit AnalysisFemaleHospitalizationHumansMaleMiddle Aged

Identifiers

PMID28646169
PMCPMC5482818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.